The era of immunotherapy in the treatment of MM was inaugurated in 2015 with the regulatory approval of mAbs targeting CD38 and SLAMF7 and the future looks bright for other immunological agents to follow in their wake as MM continues its transition from a disease heretofore considered incurable to one more resembling a manageable chronic condition. The gene discussed is SLAMF7; the disease is Miyoshi myopathy.